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Although gastrointestinal stromal tumor (GIST) is effectively treated with 
imatinib, there are a number of clinical challenges in the optimal treatment of these 
patients.  The plasma steady-state trough level of imatinib has been proposed to 
correlate with clinical outcome.  Plasma imatinib level may be affected by a number 
of patient characteristics.  Additionally, the ideal plasma trough concentration of 
imatinib is likely to vary based on the KIT genotype (genotype determines imatinib 
binding affinity) of the individual patient.  Patients’ genotype or plasma imatinib level 
may influence the type and duration of response that is appreciable by clinical 
evaluation. 
The objectives of this study were to determine effects of genotype on the 
type of response appreciable by current imaging criteria, to determine the 
distribution of plasma imatinib levels in patients with GIST, to determine factors that 
correlate with plasma imatinib level, to determine the incremental effects of imatinib 
dose escalation; and to explore the median plasma levels and outcomes of patients 
with various KIT mutations.  
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We therefore obtained KIT mutation information and analyzed CT response 
for size and density measurement of GISTs at baseline and within the first four 
moths of imatinib treatment.  In 126 patients with metastatic/unresectable disease, 
the KIT genotype of patients’ tumor was significantly associated with unique 
response characteristics measurable by CT.  Furthermore, hepatic and peritoneal 
metastases differed in their response characteristics.  A subgroup of patients with 
KIT exon 9 mutation, who received higher doses of imatinib and experienced higher 
trough imatinib levels, experienced improved progression-free survival similar to 
that of KIT exon 11 patients. 
Therefore, we have found that imatinib plasma levels were higher in patients 
with elevated Aspartate amino transferase, were women, were older, or were being 
treated concomitantly with CYP450 substrate drugs.  As expected, CYP450 
inducers correlated with a lower plasma imatinib levels in GIST patients.  Renal 
metabolism of imatinib accounts for <10%, so it was not included in the analysis but 
may affect covariates.  Interestingly, there was a trend for low imatinib levels and 
inferior progression-free survival in patients who had undergone complete 
gastrectomy. Patients with KIT exon 9 mutation in our cohort received higher 
imatinib doses, experienced higher trough imatinib levels, and experienced a PFS 
similar to that of KIT exon 11 patients. 
In conclusion, imatinib plasma levels are influenced by a number of patient 
characteristics.  The optimal imatinib plasma level for individual patients is not 
known but is an area of intense investigation.  Our study confirms patients with KIT 
exon 9 mutations benefit from high-dose imatinib and higher trough imatinib levels. 
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Chapter 1.  Introduction and Background 
1.1  Overview of GIST 
Gastrointestinal stromal tumors (GIST) were first described in 1983 by Mazur 
and Clark as a group of tumors that were non-epithelial in origin, lacked smooth 
muscle cell ultrastructural features, and did not express immunohistological 
characteristics of Schwann cells (1).  GISTs were rarely diagnosed at the time, and 
often diagnosed as gastrointestinal smooth muscles tumors (GI leiomyosarcoma, 
leiomyoblastoma, or leiomyoma), until research revealed in 1998 that most GISTs 
experience gain-of-function activating mutations in the KIT prot-oncogene (2).  This 
discovery led to increased study of the biology of GIST and provided the first 
effective therapeutic target for therapy. 
The incidence of GIST in the United States is approximately 5,000 new 
cases annually, or about 6.8 per million people (3).   Most GISTs arise from the 
stomach (60%) or small intestine (25%), but may also arise from the colon and 
rectum (10%), or the esophagus, omentum, mesentery, and rarely the 
retroperitoneum.  GISTs account for 14% of all tumors of the small intestine, about 
2% of all stomach tumors, and 0.1% of all colon tumors diagnosed (4, 5).  The 
median age of GIST diagnosis is 58 years, GIST is rarely diagnosed in children with 
only ~3% diagnosed before the age of 21 (6, 7).  In a US study from 1992-2000, 
based on Surveillance Epidemiology and End Results (SEER), there was a slight 
gender bias of GIST in men (55%), whereas several other population-based studies 
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in Europe and Asia found an equal incidence among men and women (8, 9).  No 
predisposing factors have been identified to date (10). 
GISTs are thought to arise from the interstitial cells of Cajal (ICC), 
pacemaker cells that control gut motility, and this supported by recent genomic 
research that shows that GISTs display a distinct gene expression profile from that 
of other soft tissue sarcomas (11).  Immunohistochemically, 95% of GISTs stain 
positively for the KIT protein, irrespective of the site of origin, histologic 
characteristics, or biology of the individual tumor, making KIT expression a key 
diagnostic marker of the disease (8, 10, 12, 13).  Mast cells, germ cells, 
hemopoietic stem cells, and melanocytic cells also express KIT, and so 
immunostaining of CD34, a sialylated transmembrane protein expressed in GISTs, 
is also used diagnostically (2).  Protein kinase C (PKC)-theta, an isoform of PKC, is 
highly expressed and useful to identify the rare subset of GISTs that do not express 
KIT (~5%) (14-16).  GISTs may also have positive staining for smooth muscle actin 
(SMA, 30-40%) but are generally negative for desmin, an intermediate filament 
protein found in muscle, and negative for S-100, a neural cell marker, in ~95% of 
cases (10, 17).  A proper diagnosis of GIST is often only reached through a careful 
comparison of pathological and clinical findings. 
Surgery is the incipient therapy for patients with resectable primary disease 
and complete resection is achieved in approximately 70% of patients (18).  
Approximately 54% of completely-resected patients survive for 5 years without 
further therapy, 40% recur at a median of 2 years post-surgery, and recurrence 
often involves the peritoneum and liver (18, 19).  Outcome of GIST patients upon 
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recurrence is poor (19).  About half of patients are metastatic or unresectable at the 
time of presentation (20).  Patients with advanced or inoperable disease have 
historically had limited treatment options, prior to 2001.  Response to 
chemotherapy, such as doxorubicin, ifosfamide, temozolomide produced response 
rates of 5 to 10% (21-23). Radiotherapy has little disease management role in GIST 
(24).  Therefore, more effort was placed into understanding the underlying biology 
of GIST and the KIT oncogene to develop better therapies.  In 2001, imatinib was 
found to potently inhibit autophosphorylation of the tyrosine kinase receptor KIT 
(25).  The notable impact of imatinib therapy in GIST and its mechanisms are 
discussed further in subsequent sections, below. 
1.2  KIT and KIT Receptor Activation 
Overexpression of the KIT protein, a product of the KIT gene, is a defining 
feature of GIST (26).  A receptor tyrosine kinase (type III), KIT is homologous to 
platelet-derived growth factors α/β (PDGFRA/B) and also shares homology with 
colony stimulating factor-1 receptor (CSF-1R).  Functional investigation of KIT 
began in the 1920’s, and v-KIT was cloned from the Hardy-Zuckerman sarcoma 
virus (HZ4-FeSV), a strain of feline sarcoma viruses isolated from a feline 
fibrosarcoma tumor in 1986 (6, 27, 28).  It was identified as a proto-oncogene, 
localizing in humans to chromosome 4q11-q12 and encoding a 145 kilodalton 
transmembrane glycoprotein (28, 29).  KIT is critical to the function of interstitial 
cells of Cajal and to normal gastrointestinal peristalsis, and also plays a role in 
hematopoiesis, melanogensis, and gametogensis (30-32). 
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The KIT gene encodes a 976 and 972 amino acid protein divided into 19 
exons, with four extracellular amino acids (GNNK) absent in one isoform (33, 34).  
The functional difference between the two isoforms is not known, both are 
expressed in murine and human normal tissues, and both are simultaneously 
expressed in KIT positive tissues (35).  The 19 exons of KIT encode an extracellular 
ligand-binding domain (exons 2-5), a region thought to promote dimerization of the 
receptor (6-7), an intracellular juxtamembrane region (exon 11), an ATP binding site 
(exons 12-14), two intracellular catalytic domains (exons 13, 16-19 respectively), 
and a kinase insert (exon 15), represented in Figure 1 (33, 36, 37).   
KIT activation and signaling occurs through binding of its ligand, stem cell 
factor (SCF).  SCF has two isoforms, SCF220 and SCF248, both are membrane-
bound and can be cleaved to release soluble SCF, which exists in human plasma 
as a monomer (38-45).  Both SCF isoforms are capable of kit activation following 
SCF homodimerization (38).  Upon binding SCF, the KIT receptor homodimerizes, 
autophosphorylates tyrosines 567, 569, 702, 719, 728, 934, which in turn attract 
SH2 binding partners, signaling through major mediators such as 
Phosphatidylinositide-3-OH Kinase (PI-3K, binds Y719), RAS, STATs, PLC-γ (binds 
Y728), and Src family kinases (SFK, bind Y567 and Y569), GRB2 (binds Y702) and 
GRB7 (binds Y935), as shown in Figure 2 (46).  Kit-mediated cell survival occurs 
primarily via SFK and PI-3K (27, 46, 47).  Both SCF and KIT are expressed by 
numerous cells in the body, including epithelial cells, smooth muscle cells, stromal 
cells, endothelial cells, fibroblasts, and ICCs (40, 48, 49).  Signaling of KIT through 
its downstream mediators is important in normal cellular function, yet contributes to  
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Figure 1. Structure of KIT protein  
KIT structure and localization of common mutations within the highlighted exons 9, 
11, 13, 15, and 17.  The structure of KIT includes the extracellular ligand-binding 
domain, which contains 5 immunoglobulin-like loops.  This region is thought to 
promote dimerization of the receptor.  Intracellularly, KIT has an ATP-binding site, 
two catalytic domains and a kinase insert. Ig: Immunoglobulin. TK1/2: tyrosine 
kinase domains 1/2.  Reprinted with permission from Bayraktar, U et al, World J 
Gastroenterol 16:2726-2734 copyright 2010. 
. 
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Figure 2. Schematic illustration of KIT 
This figure summarizes signaling proteins activated by KIT and interaction sites on 
the receptor. Abbreviations: SCF, stem cell factor; SFK, Src family kinases. 
Reprinted by permission from John Wiley and Sons: Stem Cells 23:16–43, copyright 
2005. 
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transformation, aberrant proliferation, cell survival, and metastasis when oncogenic 
mutations are acquired (50).  These mutations are discussed in detail, below. 
1.3  Molecular Genetic Aberrations of KIT and PDGFRA in GIST 
A central pathogenic event of most GISTs, sporadic or familial, is activation 
of the PDGFRA or KIT receptor tyrosine kinase (RTK) whereby the extracellular 
juxtamembrane domain or cytoplasmic domains of the receptor develop activating, 
gain-of-function deletions or missense mutations.  These oncogenic mutations lead 
to downstream signal transduction promoting cell survival, proliferation, chemotaxis, 
and adhesion via KIT phosphorylation of substrate proteins.  Docking sites of KIT 
phosphorylation substrates are represented in Figure 2.  A broad summary of KIT 
target genes, their downstream signaling factors, and consequences of this 
interaction are presented in Table 1.  Constitutive activation of KIT is observed in 
more than 80% of GISTs.  KIT mutations occur in two general regions, some affect 
regulatory regions of the protein and modulate its enzymatic activity, while other 
mutations occur in the enzymatic region itself (51).  Four coding regions of KIT 
harbor a majority of primary mutations: KIT exons 11, 9, 13 and 17 (in order of 
highest frequency) (52).  These mutations are visualized on the KIT protein in 
Figure 3. Intracellular, juxtamembrane exon 11 mutations are most common, 
accounting for over 65% of all KIT mutations in GIST, and a diverse spectrum of 
changes occur across the region, including more than 80 deletions, missense 
mutations, and duplications described to date (53-56).  Interestingly, these 
mutations group by type as one examines KIT exon 11 from the 5’ to the 3’ end:  
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Table 1. Genes Regulated by mutations in KIT and PDFGRA 
Mutations in KIT and PDGFRA elicit a number of signaling consequences through 
downstream mediators.  Reprinted by permission from John Wiley and Sons: 
Cancer 113:1532-1543, copyright 2008. 
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Figure 3. Regions of frequent mutations in KIT and PDGFRA 
Activation of receptor by gain-of-function mutation (blue, yellow, red dots) 
independent of ligand (L) binding induces dimerization of the receptor, 
autophosphorylation of tyrosines and causes activation of downstream signaling 
pathways. Location of primary (sporadic and hereditary) and secondary (detected 
during treatment) KIT and PDGFRA mutations is indicated by blue, yellow and red 
dots, respectively. Reprinted by permission from John Wiley and Sons: 
Histopathology 53:245-266, copyright 2008. 
 10 
 
while missense mutations occur sporadically across the entire region, deletions tend 
to cluster toward the 5’ terminal region and extend into the mid-region, whereas 
insertion/duplications cluster almost exclusively at the 3’ C-terminus (51).  Exon 9 
mutations within the extracellular, ligand-binding domain of KIT, occur in 
approximately 18% of cases, are strongly associated with intestinal GISTs, and are 
almost exclusively a six base pair (bp) insertion resulting in a tandem A502_Y503 
duplication (57).  Primary mutations of KIT exons 13 and 17 are less frequent; each 
singularly identified in only one to two percent of cases, and are almost always 
missense mutations (58). KIT exon 13 mutations occur in GISTs from various 
regions of the gastrointestinal tract and are predominantly a L642G missense 
mutation, whereas KIT exon 17 mutations are twice as prevalent in intestinal GISTs 
and are often an A822L missense mutation (51, 58).  In GIST, PDGFRA mutations 
occur principally as missense mutations in exons 12 and 18, and some substitutions 
in exon 14 have been reported (59).  The most common PDGFRA mutation is an 
A842A missense mutation, which is known to be insensitive to imatinib treatment, 
and variations of this change, A842Y and A842I have been reported (60-63). 
In Familial GIST, heritable germ-line mutations in KIT or PDGFRA are 
observed, summarized in Table 2.  These patients develop hyperplasia of the ICC 
and multiple GISTs at early ages.  It is interesting to note that these hereditary 
mutations are mostly missense mutations and most, if not all, are observed in 
sporadic GIST as well, indicating the activating potential of these small changes 
(64-79). 
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Table 2. Mutations associated with Familial GIST 
Hereditary KIT and PDGFRA mutations associated with familial GIST syndrome and 
other related genetic syndromes. Reprinted by permission from John Wiley and 
Sons: Histopathology 53:245-266, copyright 2008. 
A(75) 
B(70, 77) 
C(67, 68, 72, 78) 
D(78) 
E(65) 
F(71) 
G(73, 76) 
H(66, 79) 
I(64, 74) 
J(80) 
K(81) 
L(69) 
 
(75) 
(70, 77) 
(67,68,72,78) 
(78) 
(65) 
(71) 
(73, 76) 
(66, 79) 
(64, 74) 
(80) 
(81) 
 
(69) 
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Following the advent of imatinib treatment in GIST, resistance to the drug was 
shown to occur with the acquisition of secondary mutations in KIT.  These missense 
mutations occur in KIT exons 13 and 17, are observed in addition to continued 
expression the primary mutation, and significantly decrease the sensitivity of the KIT 
receptor to inhibition by imatinib, impacting response (58).   
1.4  Prognostic Value of KIT Mutations in GIST 
Mutation of KIT and its subsequent activation is a driving factor in GIST and 
several investigators have evaluated the prognostic relevance of different types of 
KIT mutations.  As a new treatment, imatinib mesylate, was being clinically tested in 
GIST, it became important to understand the natural history of the disease and the 
influence of genetic mutation in the absence of this targeted treatment. A summary 
of the prognostic relevance of KIT mutations is presented in Table 3. 
In 2002, Singer and colleagues reviewed a group of 48 GIST patients who 
underwent resection of their tumor and presence of a KIT exon 11 deletion/insertion 
was an independent predictor of recurrence-free survival (52).  Patients with KIT 
exon 11 missense mutation experienced a five-year recurrence-free survival (5-year 
RFS) of 89% compared to all other mutations types at 40%.  Patients with a KIT 
exon 11 deletion/insertion experienced a 37% 5-year recurrence rate compared to 
all other types.  Multivariate analysis comparing KIT mutation type, tumor size, 
mitotic rate, gender, histologic type, and margin of resection revealed KIT exon 11 
deletion/insertion to be significantly associated with GIST recurrence, in addition to 
high mitotic rate (>15/30 hpf), mixed tumor histology, and male gender (52).  A 
population-based study of 177 patients from the same timeframe, 
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Table 3. GIST clinicopathological features  
Reprinted by permission from John Wiley and Sons: Histopathology 53:245-266, 
copyright 2008. 
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1990-2000 (pre-imatinib), showed that KIT mutation type was strongly associated 
with outcome (82).  Half of KIT exon 11 deletions belonged to a high risk/overly 
malignant risk group (49% of KIT exon 11 deletions belonged to this group, 
compared to approximately 30% for KIT WT, KIT exon 11 missense mutation, or 
KIT exon 11 duplication groups separately).  In radically resected patients, two-
thirds (65%) of KIT exon 11 deletion patients had recurrence of disease (31%) or 
died of disease (34%) when followed-up at five years, compared to WT KIT (17% 
recurrence, 17% death), KIT exon 11 missense mutation (0 recurrence, 13% death), 
and KIT exon 11 duplication (0 recurrence, 13% death) groups, prompting the 
authors to conclude that KIT exon 11 deletions are specifically associated with poor 
prognosis of GIST patients (82).  In pre-imatinib gastric GISTs, an increased 
frequency of liver metastasis was observed in KIT exon 11 deleted tumors 
compared to KIT WT, as well as increased mortality in this group, both facts 
statistically significant (83).  KIT exon 11 deletions also showed a trend for greater 
proliferative potential.  Analysis of Ki-67 staining, a marker of proliferation and an 
independent predictor of prognosis in gastric GISTs, revealed that Ki-67 was 
highest in KIT exon 11 deletion tumors, less in the KIT exon 11 substitution group, 
and lowest in the KIT WT group (84).  While not statistically significant, this trend, 
taken together with the significantly higher frequency of liver metastasis and higher 
mortality from disease, suggests KIT exon 11 deletions confer more of an 
aggressive profile to GIST tumors when present (83).  Similar results were reported 
in a large-scale study of 1765 gastric GISTs by Miettinen and colleagues where a 
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KIT exon 11 deletion group had a significantly higher rate of progressive disease 
versus a KIT exon 11 missense mutation group (7). 
KIT exon 11 deletions are most commonly a six base pair, two-codon 
W557_K558 deletion in as high as 67% of detected mutations (85, 86).  Missense 
mutations and larger deletions that overlap/involve codons 557 and 558, either 
together or independently, also occur.  Examining 162 patients, Martin and 
colleagues analyzed each codon separately and saw a significant drop in 5-yr RFS 
when either W557 or K558 was affected (W557: 5-yr RFS 25% vs. 75% without 
mutation; K558: 5-yr RFS: 19% vs. 76% without mutation; p<0.0001 for each).   
Examining only KIT exon 11 deletions, patients with W557_K558 deletion had a 
striking decrease in 5-yr RFS compared with other types of deletions (23% 
W557/K558 versus 74% all other deletions, Figure 4), prompting the hypothesis 
that W557_K558 deletion is a significant component of the poor clinical outcome 
attributed to all KIT exon 11 deletions (87).  This finding has been reported by two 
other investigators (88, 89). 
Loss of heterozygosity (LOH) of the KIT locus and other chromosome 4 loci 
has been documented in advanced GIST (90). Heterozygous KIT exon 11 
mutations were noted in small, early primaries, whereas homozygous KIT mutations 
were found in advanced primaries, a majority of which progressed and developed 
liver and intraabdominal metastatic implants quickly.  GISTs with KIT exon 11 
deletions or deletion/insertions were at significantly higher metastatic risk compared 
with GISTs that expressed heterozygous deletions in the same locations.  Loss of 
KIT WT allele and duplication of the KIT mutant allele is associated with a malignant  
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Figure 4. KIT exon 11 deletions portend poor outcome 
Poor outcome likely attributable to W557_K558 deletion. A) Kaplan-Meier curve for 
patients with or without KIT exon 11 deletion. B) Kaplan-Meier curve for patients 
with or without a deletion that involves codons 557 to 558 of KIT exon 11.  
Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights 
reserved. Martin, J et al: J Clin Oncol 23(25) 2005:6190-8. 
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course of disease (90).  KIT WT LOH is likely a mechanism of disease progression 
and metastasis in some advanced GISTs and could be considered an adverse 
prognostic marker. 
1.5  Imatinib Mesylate 
Imatinib was developed out of a drug discovery initiative focused on rational 
design and discovery of targeted anticancer therapies; rational, in the sense that 
they selectively targeted genes or gene products that were unique to cancer cells.  
The first such cancer-specific aberration was discovered in 1960 (91).  A 
translocation of the long-arms of chromosome 9 and 22, called the Philadelphia 
Chromosome whose resulting fusion gene produced the BCR-ABL protein, was 
found only in tumor cells and is a primary marker of chronic myelogenous leukemia 
(CML) (92).  Biochemist Nicholas Lydon developed imatinib together with Brian 
Druker and colleagues at Oregon Health and Science University beginning in 1988. 
The pair first identified a lead compound from a drug screen of inhibitors against 
protein kinase C (PKC) (93).  During optimization of this lead compound, 
investigators noticed a structural component that would also inhibit the ATP-binding 
site of BCR-ABL, but the derivative compounds were poorly soluble in water and 
had low oral bioavailability at that stage (93).  Further structural optimization ensued 
and the most-promising compound from the optimization, STI-571 (imatinib 
mesylate, Glivec, Gleevec, Novartis Pharma, Basel, Switzerland) was found to 
readily inhibit ABL activity at an IC50 0.1-0.3µM and possess both high specificity 
and oral bioavailability (94).  It was also noted that imatinib selectively inhibited KIT 
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and PDGFRA kinase activity by competing for the adenosine triphosphate (ATP)–
binding site of these receptors, found within the kinase domain (95, 96).  
Selective inhibition of tyrosine kinases is possible through the specific 
structural/conformational differences they each posses. To inhibit KIT, imatinib 
binds to the ATP-binding pocket, occupying the nucleotide-binding cleft, and 
competitively displaces ATP, thereby hindering KIT autophosphorylation and 
constraining downstream signaling through its signaling mediators (signaling 
molecules shown in Figure 2) (97).  In vitro, autophosphorylation of both wild-type 
and mutated KIT, is completely abrogated at imatinib concentrations ≥1mM (98).   
Inhibition of KIT, MAP, and phosphorylation of AKT in GIST cell lines leads to 
reduced glucose uptake, cell cycle arrest, and induction of apoptosis (99, 100).  
Targets of imatinib and downstream signaling consequences of its inhibition are 
summarized in Table 4.  The pharmacokinetics and metabolism of imatinib are 
discussed in a subsequent section, below. 
Following rapid clinical investigation, imatinib received US Food and Drug 
Administration (FDA) approval in May 2001. An overview of the development 
timeline of imatinib is presented in Figure 5.  To date, imatinib is now approved in 
Ph+ CML, GIST, as well as chronic eosinophilic leukemia, Ph+ acute lymphoblastic 
leukemia, dermatofibrosarcoma protuberans, systemic mastocytosis, and 
myelodysplastic/myeloproliferative disorders (101).  There are currently 86 active 
clinical trials with imatinib ongoing in the United States (November 2010) (102). 
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Table 4. Targets of imatinib signaling consequences 
Reprinted by permission from John Wiley and Sons: Cancer 113:1532-1543, 
copyright 2008. 
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Figure 5. Timeline of imatinib development 
Imatinib was FDA approved in 2001 following rapid clinical development, compared 
to a typical drug development timeline presented in the inset.  Less than three years 
after treatment of the first CML patient, the new drug application was file, and FDA 
approval was granted less than three months after application. GIST, 
gastrointestinal stromal tumor; PKC, protein kinase C; CML, chronic myelogenous 
leukaemia.  Reprinted by permission from Macmillan Publishers Ltd: Nat Rev Drug 
Discov 1:493-502 copyright 2002. 
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1.6   Imatinib in CML 
CML is a myeloproliferative disorder that affects hematopoietic stem cells.  
Approximately 20% of all leukemias are CML, and the incidence of this disease 
appears to be similar worldwide.  CML has an annual incidence of 1.6/100,000, 
there is a slight male predominance (1.4 to 1.3), with a median age at diagnosis of 
55 years and few patients under the age of 20 (<10%) (103).  Greater than 90% of  
CML patients possess the Philadelphia chromosomal abnormality (Ph+) (104).  
CML has three distinct disease phases: it is typically identified when a patient is in 
the chronic phase (CML-CP), largely asymptomatic but with an elevated 
granulocyte level, followed by the accelerated phase (CML-AP), where there is a 
brisk multiplication of granulocytes.  CML-AP can lead to a blast phase (CML-BP) 
similar to acute leukemia wherein metastasis, organ failure, and death can occur 
(105).  Prior to the use of imatinib, cytotoxic chemotherapies controlled the disease, 
but most patients ultimately progressed to blast phase (105, 106). 
Imatinib was quickly moved into clinical trials in 2001 and became the first 
FDA-approved TKI for treatment of Ph+CML patients in the United States.  In a 
Phase I, dose-escalating trial for patients who had failed interferon-α therapy, 53 of 
54 patients saw complete hematologic responses, typically within the first four 
weeks of therapy, seven patients achieved complete cytogenetic remissions, and no 
maximum tolerated dose was identified (107).  Two phase II studies treating CML-
AP and CML-BC patients were highly effective and imatinib showed minimal toxicity 
in these patient groups (108, 109).  Patients were treated with imatinib at 600-800 
mg once per day and the maximal tolerated dose was not reached.  Interestingly, 
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subsequent studies showed that increasing the dose above 400-600 mg daily did 
not produce significantly higher molecular responses (MMR) at 12 months, a point 
to be examined in contrast to GIST later, and while imatinib remains the first-line 
therapy in CML, increased dose is not currently supported (110, 111). 
While imatinib has transformed treatment of CML, challenges remain as a 
significant proportion of patients develop intolerance or resistance to therapy (106).  
Similarly as in GIST, resistance is acquired as patients develop missense mutations 
in the BCR-ABL fusion gene (112).  These mutations affect the conformation of the 
protein and hinder binding of imatinib, reducing its kinase inhibition of BCR-ABL 
(113).  Sequencing of CML patients resistant to therapy has identified greater than 
100 different mutations, and very few of these mutations have been identified prior 
to therapy, none in CML-CP patients (114, 115).  The presence of two or more 
mutations in a patient, or a particular T315I mutation, has also been shown to infer 
resistance to other TKI therapies currently available (116-118).  While routine 
mutational analysis is not currently employed in all centers treating CML prior to 
imatinib therapy failure, the ability to identify those at high-risk of disease 
progression, or those who would be insensitive to TKI treatment based on mutation 
status, suggests that mutation testing in CML could be highly informative in the 
future (116, 117). 
1.7   Imatinib in GIST 
Following the observation that imatinib readily inhibited KIT and PDGFRA, a 
single patient pilot study was carried out in a setting of compassionate use in 
Finland.  A 50-year-old patient with metastatic GIST, who had failed chemotherapy 
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with six previous agents, was given 400 mg once daily of imatinib beginning March 
2000.  Response, measured by 2-deoxy-2[F-18]fluoro-D-glucose positron emission 
tomography (FDG-PET) and computed tomography (CT), showed dramatic 
metabolic response, shrinkage of the tumor, and myxoid degeneration of the liver 
metastases, confirmed by biopsy after only four weeks of treatment (119).  The 
patient experienced stable disease for over one year following initiation of imatinib 
therapy.  Phase I clinical study began in the last months of 2000 in three centers in 
Europe, where 40 patients were administered varying doses of imatinib from 400 
mg to 1000 mg once daily (120). The maximum tolerated dose was set at 800 mg 
based on severe toxicity at the 1000 mg dose, and although not an objective of the 
study, a partial response rate of 53% was observed.   
Two phase II clinical studies followed, both with impressive results in a total 
of 174 GIST patients.  The studies reported an overall objective response rate of 
63% and 71%, respectively, with greater than 80% of patients achieving partial 
response or stable disease in both trials (121, 122).  The larger of the two phase II 
trials compared starting doses of 400 mg and 600 mg in 147 subjects, and reported 
five-year survival of advanced GIST patients greater than 50%, irrespective of dose 
(123).  This was followed by two large, tandem phase III trials beginning in 
December 2000. 
The first phase III clinical study enrolled 746 patients from 57 treating 
institutions in the US and Canada with the aim of determining overall survival and 
response rates of GIST patients at two different doses of imatinib (400 mg versus 
800 mg once daily) (124).  Patients who progressed at 400 mg were allowed to 
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crossover to the higher-dose arm of the study.  At a median follow-up of 25 months, 
there were no differences in progression-free survival (50% versus 53%) or overall 
survival (78% versus 73%) between the two dose groups, 400 mg and 800 mg 
respectively.  There were, however, 106 patients who progressed at the lower dose, 
increased to 800 mg resulting in 7% partial response and 32% stable disease, 
demonstrating the efficacy of higher-doses in the context of progression (124).  The 
second phase III trial conducted by a consortium of institutions in Europe and Asia 
randomized 946 patients to 400 mg and 800 mg daily starting doses (125).  At two 
years, in contrast to the North American study, overall survival was not significantly 
different between the two arms (69% at 400 mg; 74% at 800 mg), but progression-
free survival was significant (44% at 400 mg versus 52% at 800 mg, p=0.026), 
again favoring the outcome of those receiving higher doses of the drug.  The reason 
for the discrepancy between the two studies is unclear, but it is important to mention 
that KIT mutation was not evaluated between the two studies at the time and 
differences due to race and genetic background may have played a role (4).  The 
European study enrolled more patients and thus may have had greater statistical 
power to detect such differences. In retrospect, a higher dose of 800 mg showed 
better response for KIT exon 9 patients. 
The FDA approved imatinib for treatment in GIST in 2002 and it remains a 
key first-line treatment in management of GIST today.  Patients with local disease 
(single tumor) are currently treated with surgical removal of the tumor, with negative 
margins, followed by adjuvant imatinib for up to two years in some cases (10).  
Adjuvant therapy has proven efficacious in improving recurrence-free survival (RFS) 
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and overall survival (OS) after GIST resection, likely from treatment of residual 
micrometastatic disease already present in the patient at the time of primary GIST 
diagnosis (126).  Five studies have examined the benefit of adjuvant imatinib 
therapy and shown its benefit when considered together with a patient’s individual 
risk of recurrence as well as their tumor’s underlying genetic profile (126-130).  
Similarly, neoadjuvant imatinib ahead of surgery has proven advantageous through 
the cytoreduction of tumors, decreasing the risk of intraoperative tumor rupture, 
enabling some unresectable patients the opportunity of later resection, as well as 
enabling better organ preservation (126).  For recurrent or metastatic GIST, imatinib 
is a first-line therapy and may be followed by resection of residual disease if 
patients respond.  If patients do not respond at a starting dose of imatinib (typically 
400-600 mg), imatinib dosing is often increased to 800 mg to elicit response before 
selecting a second-line TKI.  Response in GIST is discussed in a subsequent 
section.  An overview of current GIST management principles is presented in Table 
5. 
Response to imatinib varies greatly based on the underlying mutation type of 
the patient’s tumor.  Patients with KIT exon 11 mutation experience a significantly 
higher response rate, increased median and overall survival, and are at reduced 
risk of progression compared to patients with a KIT exon 9 mutation, or no KIT 
mutation at all  (Figure 6) (54, 127).  From early studies of imatinib response, KIT 
exon 9 was identified as the strongest adverse prognostic factor, and it was shown 
that a higher starting dose of imatinib (800 mg) was more effective in this group of 
patients (127, 128).   
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Table 5. Key principles in the clinical management of GIST 
Reprinted from Joensuu H et al, Gastrointestinal Stromal Tumor (GIST), Annals of 
Oncology 2006, 17(Suppl 10): 208-6 by permission of Oxford University Press. 
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Figure 6. KIT exon 11 mutation portends better response  
Genotype of GIST correlates with event-free survival and overall survival.  KIT exon 
11 mutation portends better response (C) and outcome (D) on imatinib compared to 
that of KIT exon 9 or wild-type KIT for GIST patients in the CSTI571B 2222 phase II 
study. Reprinted with permission. © 2008 American Society of Clinical Oncology. All 
rights reserved. Heinrich, MC et al: J Clin Oncol. 2003 Dec 1;21(23):4342-9. 
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Resistance to imatinib can occur through the acquisition of secondary 
mutations, discussed in Section 1.3.  These mutations are not usually detected in 
the pre-imatinib, nonresistant primary tumor, but rather in recurrent nodules or 
metastatic disease exposed to imatinib, and are associated with activated KIT levels 
similar or even higher than those in untreated GISTs (133-137).  Secondary 
mutations typically arise in exons 13 and 17 of KIT, as was previously shown in 
Figure 3.  Not all mutations in this region are identical however, and 
responsiveness of some KIT exon 13 mutations (albeit typically primary 13) to 
imatinib have been reported (129, 130).  Functional analyses and molecular 
modeling of different mutations in KIT has provided meaningful evidence as to why 
secondary, and even different primary, mutations exhibit discordant influence on the 
inhibition by imatinib: each mutation affects the complex ultrastructure of the KIT 
protein and can alter the imatinib:ATP-binding pocket interaction significantly and 
uniquely (131).  Not all secondary mutations might inhibit in the same manner, as a 
KIT exon 13 T670I alteration was found to modify the binding pocket considerably, 
whereas a KIT exon 13 V654A mutation resulted in minor, relatively confined 
structural changes (131). KIT exon 17, which encodes the activation loop, makes 
close physical contact with imatinib.  Mutations such as D820Y and N822K stabilize 
the active form of the receptor and this, in turn, impedes the binding of imatinib 
(132-134).  Sub-groups of primary KIT exon 11 mutations have been reported that 
have reduced response to imatinib in some cases, such as the KIT exon 11 
mutation L576P (142, 143).  This missense mutation in the juxtamembrane region 
places considerable constraint upon the ATP-binding pocket was computationally 
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predicted to be two-times less sensitive to imatinib than wild-type KIT (135).  KIT 
exon 9 mutations are thought to distort an anti-dimerization motif in the extracellular 
region and promote spontaneous dimerization of KIT (49, 53).  In both situations, it 
is understandable to hypothesize that higher concentrations of the competitive 
inhibitor would be required and that a higher dose of imatinib could be more 
effective to overcome either binding target constraint or increased KIT dimerization. 
1.8   Therapeutic Drug Monitoring of Imatinib in GIST 
Therapeutic drug monitoring (TDM) by sampling the levels of a particular 
drug of interest in the serum or plasma of a patient can be important to ensure that 
patient stays within a therapeutic range, thereby maximizing a drug’s therapeutic 
effect.  TDM also serves to minimize toxicity and assess patent adherence to oral 
therapies (136, 137).  Therapeutic range means the area between the curve where 
drug levels are to have a therapeutic effect, with minimal toxicity (illustrated in 
Figure 7).  After administration and absorption, within a few hours a drug reaches 
its maximum concentration (Cmax,) in the blood.  This peak may be associated with 
some toxicity.  Over time, as the drug is metabolized and eliminated by the body, 
the concentration decreases and reaches its minimum concentration (Cmin), also 
called the “trough”.  Generally, a patient achieves the trough level at the time their 
next dose is scheduled.  This trough level is important that it remain above the 
lowest therapeutically effective concentration (see Figure 8).  In this study, TDM 
was used to determine a patient’s trough level and dose adjustment may follow to 
optimize this level.  The time needed for the drug concentration to decrease in the 
blood by 50% is referred to as the half-life of that drug.  After a patient has received 
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Figure 7. Therapeutic range  
Therapeutic range of a drug is the region between the effective curve of drug 
concentration and the concentration that is associated with toxicity.  Reprinted with 
permission. © Test Positive Aware Network 2005; Anderson, P. Positively Aware 
(6):3-7.  
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Figure 8.  Blood levels of a drug over time 
A drug will reach Cmax within a few hours following administration and absorption.  
Cmax may be associated with some toxicity.  Drug concentration decreases over 
time as it is metabolized and eliminated by the body until Cmin (“trough”).  Trough 
level should remain above therapeutic minimum concentration for effectiveness. 
Reprinted with permission. © Test Positive Aware Network 2005; Anderson, P. 
Positively Aware (6):3-7. 
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a drug for some time, the patient is said to be at steady-state when the rate of drug 
administration and drug elimination are equal.  Steady-state is usually achieved 
within four to five days, or in about five to seven half-lives of imatinib (138).  At 
steady-state, each subsequent dose of a drug would result in identical Cmax, Cmin, 
and area under the curve (AUC) (Figure 9). 
 Recently, significant focus has been placed upon monitoring the plasma 
imatinib levels of GIST patients after studies in CML showed that accelerated-phase 
patients benefitted from increased plasma imatinib levels.  CML-AP patients 
receiving 400 mg or 600 mg who achieved major molecular response (MMR) had 
significantly higher mean imatinib trough levels (1452 ± 649 ng/mL for MMR versus 
869 ± 427 ng/mL for non-responders) (139).  Dose level did not, however, correlate 
with this rate of MMR, indicating that not all patients at identical dose may achieve 
similar trough levels of imatinib.  Similarly, a study of 351 CML-CP patients showed 
that higher steady-state imatinib plasma levels were associated with complete 
cytogenic response, and a therapeutic minimum imatinib plasma level for CML was 
suggested at 1002 ng/mL (139, 140).  Again, patients at identical dose experienced 
a diverse range of imatinib plasma levels, illustrated in Figure 10.   
In GIST, notable interpatient variability of plasma imatinib levels was similarly 
observed in a recent, retrospective analysis of patients who received either 400 mg 
or 600 mg imatinib and dose was not associated with statistically significant 
differences in median PFS, overall survival or response (141, 142).  Dividing the 
patients into quartiles based on increasing plasma imatinib level, however, revealed 
that patients with the lowest plasma levels of imatinib (quartile 1) experienced 
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Figure 9. Concentration time curve at steady-state 
Steady-state is achieved when the rate of drug administration and drug elimination 
are equal, usually within one to two weeks, or in about five half-lives of a particular 
drug (143).  At steady-state, each subsequent dose of a drug would result in 
identical Cmax, Cmin, and area under the curve (AUC). Reprinted with permission. © 
Test Positive Aware Network 2005; Anderson, P. Positively Aware (6):3-7. 
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Figure 10. Patients experience diverse trough imatinib levels  
Distribution of trough imatinib levels at 400 mg daily at steady-state on day 29 
(n=351). The vertical dashed lines represent 25th, 50th (median), and 75th 
percentiles. Reprinted with permission of The American Society of Hematology 
(ASH) from Larson et al. Imatinib pharmacokinetics and its correlation with 
response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of 
the IRIS study. Blood 111:4022-4028, 2008; permission conveyed through 
Copyright Clearance Center, Inc. 
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a significantly shorter time to progression, displayed in Figure 11, and Demetri and 
colleagues assigned a therapeutic lower threshold of 1100 ng/mL which 
corresponded to the cutoff of this lower quartile (142).  A benefit for those with KIT 
exon 9 mutation was not observed in this study due to the low number of patients 
included.  A subsequent small study by Widmer and colleagues did observe a 
longer time to progression for KIT exon 9 patients treated with 800 ng/mL imatinib, 
but further analysis of the response in relation to plasma imatinib level is required in 
this group (144, 145). 
1.9   Pharmacokinetics of Imatinib 
Imatinib mesylate has favorable pharmacokinetic (PK) characteristics in both 
GIST and CML (146).  The drug is rapidly absorbed and has a high oral 
bioavailability (<97% for both solution or capsule form) (147).  Serum proteins avidly 
bind the drug upon absorption and peak serum concentrations are reached two to 
four hours following administration (148).  Imatinib has a linear dose-exposure 
relationship in population-PK models, its terminal half-life is approximately 20 hours 
allowing for once-daily dosing (4).  After once-daily dosing, drug accumulation of 1.5 
to three-fold is observed and steady-state is achieved within four to five days (149). 
The metabolism of many medications, including imatinib, is dependant upon 
the cytochrome P450 (CYP450) enzymes found in the liver and less extensively in 
the gastrointestinal tract (150).  There are greater than 50 CYP450 enzymes, but 
over 90% of drugs are metabolized by the following isoenzymes: CYP1A2, 
CYP2C9, CYP2D6, CYP3A4, CYP3A5 (151, 152).  Clinically significant drug 
interactions are largely a result of altered CYP450 metabolism and close monitoring  
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Figure 11. Distribution of trough imatinib levels 
Plasma levels correlate to response in a group of unresectable/metastatic GIST 
patients. A) Distribution of imatinib trough concentration of GIST patients at steady-
state receiving either 400 mg or 600 mg daily.  Investigators subdivided by quartile 
for efficacy analysis and determined a 1100 ng/mL recommended minimum, which 
corresponded to the lowest quartile.  B) Kaplan-Meier comparing time to 
progression for the four quartiles shows that patients with lower imatinib trough 
levels progress faster. Reprinted with permission. © 2008 American Society of 
Clinical Oncology. All rights reserved. Demetri, G et al. 27(19), 2009: 3141-3147.
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is required when patients are given one or more drugs that influence CYP450 
metabolism to avoid interaction and/or therapeutic failure (153-158).  A drug that 
causes inhibition of any CYP450 enzyme is referred to as a “CYP450 inhibitor.”  
Inhibition usually occurs quickly after an inhibitor drug is added to a patient’s 
medications and resolves upon clearance of the drug.  A drug that increases 
CYP450 enzyme activity is called a “CYP450 inducer” and this occurs via increased 
enzyme synthesis.  Unlike inhibitors, CYP450 induction may take from days to 
several weeks as more enzyme is produced upon initiation of a CYP450-inducing 
drug; likewise, a delay may exist for induction to cease once that drug is 
discontinued (150). 
There are several patterns of drug-drug interactions to consider when 
sequentially adding or removing drugs from a drug regimen, but the interactions that 
are potentially important in the case of imatinib are as follows (159):  
 
CYP450 inhibitor added to a CYP450 substrate - adding a CYP3A4 or CYP3A5 
inhibitor to imatinib (a CYP3A4/3A5 substrate) could result in higher plasma 
imatinib levels.  Additionally, stopping a CYP3A4/3A5 inhibitor that a patient 
received prior to induction of imatinib may result in lower plasma imatinib 
levels.  Conversely, as imatinib is itself a CYP3A4/CYP2D6 inhibitor, one 
might experience higher levels of both imatinib and any other CYP3A4 or 
CYP2D6 substrate drug with which it was co-administered.  Higher imatinib 
plasma levels may result in increased efficacy as well as toxicity. 
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CYP450 inducer added to a CYP450 substrate - adding a CYP3A4 or CYP3A5 
inducer to imatinib could result in decrease plasma imatinib levels and this 
drop may be delayed as mentioned above.  Decreased plasma imatinib 
levels below a therapeutic minimum could be associated with decreased 
efficacy. 
Removal of CYP450 inhibitor – discontinuation of a CYP3A4 or CYP3A5 inhibitor 
may result in a decrease of plasma imatinib levels.  Again, decreased plasma 
imatinib levels below a therapeutic minimum could be associated with 
decreased efficacy. 
Removal of CYP450 inducer - discontinuation of a CYP3A4 or CYP3A5 inducer 
may result in increased plasma imatinib levels, with possible delay.  As 
before, higher imatinib plasma levels may result in increased efficacy or 
toxicity. 
Keeping these patterns of interaction in mind, therapeutic drug monitoring of GIST 
patients may be critically important to ensure that they a) maintain a therapeutic 
minimum plasma level, and b) do not experience any adverse drug reactions with 
concomitant medications, and c) do not experience intolerable toxicity while on 
imatinib.  Dose adjustment may be necessary based on clinical judgment.  
Interactions of significant effect with imatinib are discussed, following. 
Imatinib is a substrate of the CYP3A4 and CYP3A5 isoenzymes, and it is an 
inhibitor of CYP3A4 and CYP2D6 as well, effects of which are discussed below 
(160).  Imatinib is extensively metabolized the cytochrome P450 (CYP) enzymes of 
the liver into its major metabolite, N-desmethyl-imatinib (CPG74588) and other 
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metabolites, then eliminated via biliary/fecal excretion (138).  At steady-state, the 
concentration of CPG74588 is approximately 17% that of imatinib and CGP74588 
retains the antitumor properties of imatinib; it is currently unclear if the additional 
metabolites are active (4).   
It has been shown that co-administration of rifampicin, a CYP450 inducer, 
increases the clearance of imatinib (161).  Similarly, St. John’s Wort, an over the 
counter herbal medication commonly used for depression, increases imatinib 
clearance by up to 43% (162).  Imatinib is an inhibitor of CYP3A4, as well as 
CYP2D6 and co-administration of imatinib with simvastatin, a 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, results in elevated 
levels of both drugs (163).  Ritonavir, a potent CYP3A4 inhibitor, has been shown to 
have little effect on imatinib steady-state levels (164).  Several other 
pharmaceuticals for cancer patients may achieve toxic levels when co-administered 
with imatinib, such as alprazolam, clindamycin, clonazepam, cortisol, ethinyl 
estradiol, and verapamil (163).  Imatinib shares a biotransformation route with 
acetaminophen via CYP3A4 and preclinical studies have suggested an interaction 
between the two drugs leading to irreversible hepatoxicity (165, 166).  Patients are 
anecdotally advised to avoid daily use or excessive amounts of acetaminophen 
(167).  
Patients with GIST commonly experience gastric upset, both from their 
disease and as a side effect of treatment with imatinib, making co-administration of 
antacids or proton-pump inhibitors (PPI) common.  The PPI omeprazole does not 
significantly affect imatinib pharmacokinetics compared to another TKI used in 
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GIST, dasatinib, where PPI can decrease peak concentrations as much as two-fold 
(168).  Similarly, magnesium/aluminum-based antacids have shown no effect on the 
pharmacokinetics of imatinib (169).   
1.10  Response Evaluation of GIST by CT 
Multiple imaging modalities have proven informative in assessing response 
or GIST to therapy.  In 2000, international guidelines for the size-based evaluation 
of tumor response were published, entitled the Response Evaluation Criteria of 
Solid Tumors (RECIST) (170).  RECIST identified contrast-enhanced CT and 
magnetic resonance imaging (MRI) as the best-reproducible methods for target 
lesion measurement in solid tumors, including GIST.  Additionally, positron emission 
tomography (PET) employing fluorine-18—flourodeoxyglucose (18FDG) is highly 
sensitive in visualizing changes in tumor glucose metabolism and shows GIST early 
response (171).  In patients with KIT-expressing metastatic GIST, early response to 
imatinib treatment, as measured by 18FDG-PET, correlates with significantly 
improved progression-free survival after one year (172, 173).  Unfortunately, 18FDG-
PET is not universally accessible and is cost-prohibitive.   Additionally, some small 
GISTs (<4.7 cm) have no discernable uptake of FDG, make them inutile as baseline 
images or comparators to post-treatment imaging (174).  Contrast-enhanced CT is 
widely available, less expensive, and particularly with the latest-generation 
multidetection scanners, provides significant anatomic detail and spatial resolution 
compared to PET, making it the imaging modality of choice in GIST (175, 176). 
Gastrointestinal stromal tumors can occur throughout the GI tract; the most 
frequent site of metastasis is the liver and the peritoneum (177).  These highly 
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vascular tumors have significant contrast enhancement when visualized by CT 
(176).  GISTs responding to treatment by imatinib generally decrease in size, which 
may not be appreciable for several weeks (178).  Some responding GIST tumors 
actually increase in size and current opinion attributes this to intratumoral 
hemorrhage, necrosis, and myxoid degeneration within the tumor (176).  Enhancing 
nodules within the tumor resolve, vascularity decreases, and GISTs become 
homogenous and hypodense in response to effective therapy.  Changes in density 
are appreciable within one to four weeks of treatment initiation (178).  An example 
of response to imatinib therapy in GIST is shown in Figure 12.   
Surveillance of GIST during and post-treatment with contrast-enhanced CT is 
also important to detect evidence of recurrence or progression, which may occur in 
the form of clonal, resistant nodules (179).  The appearance of intratumoral 
enhancing nodules within a hypodense lesion are often a sign of progression and 
these may occur without a size change in the overall tumor (176).  Often, these 
enhancing lesions represent clonal development of tumor cells bearing additional 
resistance mutations in KIT (180-182).  Appearance of focal progression within a 
principally-responding GIST tumor do not necessarily signal that imatinib therapy 
should be stopped, as alternative, complementary therapies may be available, such 
as radio frequency ablation (RFA) (176).  
 Recent studies have proven that evaluating GIST using traditional size-based 
criteria can dramatically underestimate response (173, 183-185).  Using WHO 
criteria (sum of the products of two-dimensional tumor measurements) or RECIST 
criteria (sum of the longest unidimensional tumor measurement), one might 
 42 
 
 
Figure 12. Representative response of GIST metastases 
Advanced GIST with multiple hepatic and peritoneal metastases in a 61-year old 
woman with recurrent small bowel GIST.  A) Pre-treatment contrast-enhanced CT 
reveals multiple, bulky, heterogeneous, hypervascular masses in the liver and 
peritoneum (arrows). B) Follow-up CT after six months of 400 mg imatinib daily  
shows that the lesions have reduced in size and have become significantly 
hypodense.  Such results typify good response to imatinib. 
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misclassify a responding GIST as stable disease or even progressing upon size 
enhancement with imatinib therapy (176).  Subjective evaluation criteria account for 
tumor size, extent/degree of CT enhancement, presence of tumor vessels, and 
presence of solid nodules within the tumor and are thought to best indicate overall 
response of a GIST tumor, yet such subjective criteria are not wholly quantitative 
and require an experienced radiologist familiar with the response patterns of GIST.  
Modified, objective criteria have been developed which predict response with 
greater accuracy in GIST compared to RECIST, hereinafter referred to as “Choi 
criteria”.  Choi criteria consider a 10% (or greater) decrease in summed 
unidimensional tumor size or 15% decrease in tumor radiodensity a more sensitive 
qualifier of response in GIST (186).  These criteria for response are summarized in 
Table 6.  Though Choi criteria have been validated and RECIST shown to be an 
inadequate measure of clinical benefit, most if not all studies evaluating prognostic 
and predictive markers in GIST still use RECIST (184). 
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Table 6. Modified Choi response criteria of GIST 
Criteria defining radiologic characteristics of complete response (CR), partial 
response (PR), stable disease (SD), and progressive disease (PD) are presented. 
Reprinted from Choi, H et al: J Clin Oncol 25 (13), 2007: 1753-1759; Reprinted with 
permission. © 2008 American Society of Clinical Oncology.  All rights reserved.   
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1.11  Specific Aims of the Study 
There are a number of clinical challenges in the optimal treatment of GIST 
patients.  Since KIT genotype influences the binding of imatinib (129), the optimal 
plasma trough concentration of imatinib is likely to vary based on the KIT genotype 
of the individual patient.  Patients’ genotype may influence the type of response that 
is appreciable by clinical evaluation, for example, by CT.  Patient clinical response, 
if not homogenous and clear-cut in reflex to imatinib treatment should be carefully 
defined so as to better recognize effective treatment and/or earlier no-response of 
patients based on genotype.  
Even though imatinib is an orally administered therapy, it is unclear whether 
patients who have received gastrectomy or small bowel resection absorb adequate 
levels of imatinib.  Although standard of care is to increase imatinib dose at the time 
of progression, there is no data to show that a dose escalation results in an 
increase in the plasma trough concentration of imatinib in GIST patients. 
The objectives of this study are to determine effects of genotype on the type 
of response appreciable by current imaging criteria, to determine the distribution of 
plasma imatinib levels in patients with GIST, to determine factors that correlate with 
plasma imatinib level, to determine the incremental effects of imatinib dose 
escalation; and to explore the median plasma levels and outcomes of patients with 
KIT exon 9 mutation. To that end, we have the following specific aims: 
1. To determine whether specific KIT mutations correlate with clinical 
outcomes of GIST patients treated with imatinib.  Hypothesis: Patients with KIT 
exon 11 mutations affecting codon 557 respond to imatinib with maximal reductions 
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in tumor size and greater decreased radiodensity compared to other KIT exon 11 
mutations. If the hypothesis is true, then patients with KIT exon 11 mutation 
affecting codon 557 will respond to imatinib with a decrease in tumor IV contrast 
uptake on CT and significant decrease in tumor size.  If the hypothesis is not true, 
then other KIT exon 11 codons, other exons of KIT, and specific types of mutational 
changes will be evaluated for type of CT response. 
2. To determine whether imatinib plasma levels correlate with clinical 
outcomes of GIST patients treated with imatinib - Hypothesis: standard dosing 
of imatinib in GIST patients results in sub-therapeutic treatment levels for some 
patients.  Higher imatinib plasma levels correlate with better clinical response. If the 
hypothesis is true, then clinical response, as assessed by CT (Choi Criteria), will be 
associated with higher imatinib plasma levels, irrespective of imatinib dose.  If the 
hypothesis is not true, then this may indicate resistance to the drug in some patients 
(ie secondary mutation present), which could be screened.   
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Chapter 2.  Materials and Methods 
2.1  Plasma Level Testing and Calculation of Adj‐Cmin 
From May 2008 to September 2010, patients with gastrointestinal stromal 
tumor (GIST) underwent therapeutic drug monitoring (TDM) at the University of 
Texas M.D. Anderson Cancer Center (UTMDACC), in Houston, Texas.  Patients 
received a variety of doses ranging from 100 to 1200 mg based on clinical 
indication. Dose escalation occurred following disease progression, identification of 
KIT exon 9 mutation, or in patients with a notably low imatinib plasma level as per 
current clinical practice guidelines.  Dose reduction occurred in the setting of 
unacceptable toxicity.  
Plasma imatinib levels were determined using a validated liquid 
chromatography-tandem mass spectrometry assay by Avantix Laboratories, 
Newark, DE.  Per patient, at least 5mL of blood was collected in K2-EDTA tubes by 
direct venipuncture, centrifuged at 1500Xg for ten minutes to achieve plasma 
separation, and plasma samples stored below -20°C until analysis.  Protein 
precipitation/dilution samples were prepared using 100 µ L of patient sample, 
followed by isocratic separation on a Sepax GP-C18, 3 µ m, 2.1 x 100 mm LC 
column  (3.5 minutes run time @ 0.4 mL/min).  Samples were then analyzed by 
LC/MS/MS (MRM, electrospray positive ion mode) with an internal calibration 
method to detect both imatinib ST1571 (from 10 – 7500 ng/mL in plasma) and its 
metabolite CGP74588 (from 50 – 1500 ng/mL in plasma) in the samples. 
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Samples were drawn over a wide time window and adjusted trough imatinib 
concentrations (Adj-Cmin) were calculated from the observed trough levels according 
to the algorithm validated by Y Wang and colleagues (187). 
Adj-Cmin = Cmeasured*exp (0.041 Δτ) 
where Cmeasured is the observed plasma level at the time of sampling, and Δτ is the 
time since last imatinib dose.  Adjustment of trough levels is achieved by multiplying 
the observed plasma imatinib level (Cmeasured ) and time since last dose (Δτ) by an 
elimination rate constant, (ke), determined using the clearance and volume of 
distribution for imatinib.  Since it is assumed that the actual ke is not known in each 
patient in the clinical setting, the algorithm is corrected using a typical ke of 
0.041hr−1. For patients with typical ke, blood samples can be collected at any time 
point in the elimination phase and correctly adjusted using the algorithm with no 
error, whereas patients with high ke should conservatively be drawn within ±6hrs 
normal dose time to keep the residual error of the adjusted trough low (187). 
No patient was drawn more than twelve hours after his or her regularly 
scheduled dosing time, tao (τ).  Samples were excluded from patients who were 
non-adherent to therapy (by patient report) or had experienced dose interruption 
within five days of sampling, and from those who took imatinib too close to the 
sampling time less than six hours for all dose schedules). 
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2.2  Patient Response Assessment 
Response to therapy, measured by CT, was assessed at baseline, two 
months and four months after first imatinib exposure.  CT was performed with a 
LightSpeed or Hi-Speed Advantage helical scanner (GE Healthcare) using a 
monophasic scanning technique.  The abdomen and pelvis were scanned at 5.0- or 
7.0-mm collimation from the level of the diaphragm to the pubic symphysis. The 
scanning delay was 60 seconds after the start of administration of 150 mL of 60% 
nonionic contrast agent (Optiray 320, Mallinckrodt) at a rate of 3 mL/sec.  Triphasic 
scanning technique was used in some patients, with scanning delays of 30, 60, and 
120 sec for the early arterial, late arterial, and portal venous phases, respectively, 
after IV injection of the contrast agent at a rate of 5 mL/sec. 
Using an independent workstation available in Diagnostic Imaging 
UTMDACC, the CT attenuation coefficient (radiodensity) of each tumor was 
measured in Hounsfield units by drawing a region of interest circumscribing the 
margin of the tumor in post-contrasted images. In patients scanned using triphasic 
techniques, the portal venous phase images were used for the tumor density 
measurement.  The tumor density change (%) from the pretreatment evaluation to 
the two- and four-month evaluation was computed for each lesion, and the average 
percentage of change was then computed for each patient. 
Tumor size was then measured at the longest cross-sectional dimension of 
each lesion.  The percentage of change in the sum of the longest dimensions from 
the pretreatment evaluation to the two- and four-month evaluation was then 
computed for each patient. 
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Response was classified according to Choi criteria as complete response 
(CR, no radiographic evidence of GIST) partial response (PR, > 10% decrease in 
GIST size or a > 15% decrease in GIST radiodensity), stable disease (SD, less than 
10% decrease or increase in GIST size and does not meet criteria of PR by 
radiodensity), progressive disease (PD, > 10% increase in GIST size), or no data 
(ND, patient underwent resection and no response could be assessed) (184). 
2.3  GIST Genotyping 
Genotype of GIST patient samples were characterized in the Molecular 
Diagnostics Laboratory at UTMDACC for clinical purposes or in the sarcoma 
research laboratory at our institution.  Tumor tissue was assayed for KIT and 
PDGFRA mutation as previously described.  Specific paraffin blocks containing 
tumor were identified and hematoxylin and eosin (H&E)-stained and unstained 
four mm-thick sections were obtained. Areas containing viable tumors were marked 
on the H&E slides and the slides were submitted for molecular analysis. Genomic 
DNA samples were isolated from microdissected paraffin-embedded slides using a 
QIAamp DNA minikit (Qiagen, Germantown, MD, USA) according to the 
manufacturer's instructions. One milligram Chelex-100 resin (Bio-Rad, Hercules, 
CA, USA) was added, mixed to a slurry, and incubated at room temperature for 
fifteen minutes. After centrifugation at 10,000 g for five minutes, the supernatant 
was decanted for use.  
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Polymerase chain reaction (PCR) for sequencing of KIT and PDGFRA was 
carried out using the following oligonucleotides:  
KIT exon 9 (180bp product)  F 5’-TTTCCTAGAGTAAGCCAGGGC-3’  
R5’-GTTGTAAGCCTTACATTCAACCG-3’ 
KIT exon 11 (193bp)   F 5’-CTATTTTTCCCTTTCTCCCC-3’  
R5’-TACCCAAAAAGGTGACATGG-3’ 
KIT exon 13 (176bp)   F 5’-TTTGCCAGTTGTGCTTTTTG-3’  
R5’-CAGCTTGGACACGGCTTTAC-3’ 
KIT exon 17 (185bp)   F 5’-TGGTTTTCTTTTCTCCTCCAA-3’  
R5’-TGCAGGACTGTCAAGCAGAG-3’ 
PDGFRA exon 12 (261bp)   F 5’-TCCAGTCACTGTGCTGCTTC-3’  
R5’-GCAAGGGAAAAGGGAGTCTT-3’ 
PDGFRA exon 18 (252bp)  F 5’-ACCATGGATCAGCCAGTCTT-3’ 
R5’-TGAAGGAGGATGAGCCTGACC-3’   
PCR was carried out in a total volume of 25 µL containing 50 to 100 ng of genomic 
DNA and 0.25 acral lentiginous DNA polymerase (Bioline, London, UK). Mutations 
in these genes were identified by sequencing the PCR products on a 3730 × 1 DNA 
analyzer (Applied Biosystems, Carlsbad, CA, USA) in the Molecular Diagnostic 
Laboratory or the Nucleic Acid Core Facility at UTMDACC. Control wild-type KIT 
and PDGFRA sequences were used for comparison to evaluate for mutation using 
FinchTV 1.4.0 software (Geospiza, Inc., Seattle, WA) on Mac Operating System 
10.5.8.  Sequencing was carried out for KIT exons 9 and 11 first, followed by KIT 
exons 13 and 17 if no results, then followed by sequencing of PDGFRA exons 12 
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and 18 if KIT was wild-type.  Incomplete sequencing of PDGFRA is available, as a 
result. 
2.4  Statistical Analysis 
 The minimum study size was determined as follows: assuming exponential 
PSF and at least 12 months median PFS, then 90 patients would be sufficient to 
detect a 100% difference in PFS of 24 months with 83% power, based on a one-
sided 0.025 level test.  These estimates are based on the study by Demetri and 
colleagues (142). 
Patients undergoing a planned dose escalation, for example following 
surgery, who were at a known less-than therapeutic dose at the time of TDM 
analysis were used only for the PK analysis and were excluded from any long-term 
outcome analysis. 
The statistical association between immunohistochemical expression of KIT, 
KIT genotype, and diagnoses was investigated using Fisher's exact test, Kruskal–
Wallis test, and the Spearman's rank correlation when the ordering of both factors 
was important. The level of significance was set at 5%.  Covariates analyzed 
included: age, gender, race, body surface area (BSA), KIT mutation status (wild-
type, exon 11 mutation, exon 9 mutation, or other), location of the primary tumor 
(esophageus, stomach, small bowel, or colon/rectum), primary tumor versus 
metastatic disease, lab values on the day of TDM such as total bilirubin, aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), and presence of co-
medications classified as cytochrome P450 (CYP450) inducers, inhibitors, or 
substrates. We also analyzed whether presence of full gastrectomy, proximal partial 
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gastrectomy, or distal partial gastrectomy correlated with altered plasma imatinib 
concentrations. 
The distribution of each continuous variable was summarized by its mean, 
standard deviation and range.  The distribution of each categorical variable was 
summarized in terms of its frequencies and percentages.   
Since multiple measurements from a patient were collected/evaluated, a 
linear mixed model accounting for within-patient correlation was used. Marginal 
effect model and random effect model were conducted separately (188). Marginal 
effect model means the average response over the sub-population that shares a 
common value of the covariate. The coefficient was to describe the change in the 
average response for a unit change in the covariate for the entire population. As for 
the random effect model, the underlying idea is that a natural heterogeneity exists 
between individuals and this heterogeneity can be represented by a probability 
distribution. The coefficient under the random effect model describes the change in 
the average response for a unit change in the covariate for a particular subject.   
Covariate distributions for this cohort and the retrospective patients were 
compared using generalized Fisher exact tests for categorical variables and 
Wilcoxon tests for numerical valued variables.  Logistic regression was conducted 
to evaluate the effect of various factors on patient response. Kaplan-Meier curves 
(1958) were used to estimate unadjusted OS and PFS (189). Log rank tests were 
used to compare each time-to-event variable between groups like mutation groups.  
The Cox proportional hazards regression model (1972) was used to evaluate the 
ability of patient prognostic variables or treatment group to predict OS and PFS time 
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(190). The t-test was conducted to assess if there is difference between different 
sites (liver vs. peritoneal) regarding size change and density change; the ANOVA 
test was used to assess if there is difference across mutation types (9, 11, and wild 
type) regarding liver/peritoneal size and density change. All computations and were 
carried out in SAS version 9.1 and S-Plus version 8.0.  
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Chapter 3. Specific KIT Mutations Correlate with Clinical Outcomes 
of GIST Patients Treated with Imatinib 
3.1  Introduction 
Genotype of GIST is significantly associated with progression-free survival, 
rate of recurrence, response to therapy (imatinib or other), as well as pathological 
correlates (54, 129).  Genotype, and KIT mutation subtype, is associated with 
differential mitotic rate and histology of different GISTs (87).  It is therefore logical to 
investigate whether genotype influences response to imatinib therapy, as measured 
by CT. 
We hypothesize that patients with KIT exon 11 mutations affecting codon 557 
are more sensitive to the antitumor activity of imatinib in GIST.  Therefore, GISTs 
will respond to imatinib with maximal reductions in tumor size and greater decrease 
in radiodensity compared to other KIT exon 11 mutations. If the hypothesis is true, 
then GIST patients with KIT exon 11 mutation affecting codon 557 will be more 
likely to have better clinical outcomes such as progression-free survival and down 
staging of the tumor to enable surgical resection.  If the hypothesis is not true, then 
other KIT exon 11 codons, other KIT exons, and specific types of mutational 
changes will be evaluated in order to identify the genotype with best clinical 
outcome. 
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3.2  Results 
In total, 531 consecutive GIST patients whose pathology was reviewed at 
UTMDACC were sequenced for the presence of KIT and PDGFRA mutations as 
previously described.  In all, 321 KIT exon 11 mutations were identified, 49 KIT 
exon 9 mutations, 10 KIT exon 13 mutations, 9 KIT exon 17 mutations, and 11 
PDGFRA mutations (exon 12 n=3, exon 18 n=8) were identified.  KIT was 
determined wild-type in 51 samples (no KIT exon 9, 11, 13, or 17 mutation 
identified) and incomplete sequencing was obtained on 80 samples where, for 
example, KIT exons 9 and 11 were negative, but insufficient material was available 
for further sequencing.  A summary of sequencing findings is presented in Table 7. 
 KIT exon 11 mutations represented a majority of mutations identified and 
significant diversity was observed in the type of mutations across this region.  
Deletions were identified in 158 cases, 82 cases displayed a missense mutation of 
one or more codons, deletions plus missense mutation accounted for 59 cases, 
while duplications and duplication with missense mutation occurred in 17 and 5 
cases, respectively.  The most frequent KIT exon 11 mutations identified, of any 
type, were a W557_K558 deletion (n=46), an L576P missense mutation (n=18), and 
a W557G missense mutation (n=16).  All mutations identified were mapped together 
and sorted by earliest codon affected, represented in Figure 13. While some 
exceptions were noted, deletions were observed most frequently in the N-terminal 
to mid-region of the exon.  The majority of missense mutations also occurred in the 
N-terminal to mid-region of the exon, excluding L576P.  Duplications clustered 
primarily in the C-terminal region of the exon. 
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Table 7. Mutations identified in 528 GIST patients 
Sequencing results from 531 GIST reviewed at UTMDACC are presented. 
Incomplete sequencing of 80 cases, where only partial KIT testing could be 
obtained for various reasons are included in the combined percentages. Note: a 
single case where W582[stop] was identified in KIT exon 11 has been accounted as 
a deletion in this table. 
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Figure 13. Frequency of KIT exon 11 mutations in our population 
KIT exon 11 alterations of 132 distinct types were identified in 321 patients.  A wild-
type KIT exon 11 codon sequence map appears at the top of the diagram.  Below 
the wild-type sequence is each of the 132 distinct mutations identified in the order of 
earliest codon affected.  The number of patients identified for each mutation type is 
displayed on the right-hand side of the figure, while the frequency of each mutation 
to each individual KIT exon 11 codon is represented graphically at the bottom.  
While some exceptions were noted, deletions were observed most frequently in the 
N-terminal to mid-regions of KIT exon 11.  The majority of missense mutations also 
occurred in the N-terminal to mid-regions, excluding L576P.  Insertions and 
duplications clustered primarily in the C-terminal region. 
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 Forty-six patients with GIST were found to have the most common KIT exon 
9 mutation in GIST, a duplication of A502-Y503.  Two new KIT exon 9 mutations 
were identified in 3 GIST patients: two patients had S476I while one patient had 
A507-F508 duplication (Figure 14 A, B).   Identification of the two S476I mutations 
verifies one previously reported case, whereas the A507_F508 duplication was 
found to be unique (186-188). Although these novel mutations have not been 
proven to be oncogenic, they are in the region of KIT exon 9 that is aberrant in 
GIST.  
 From this database of GIST sequencing information, patients were identified 
for whom clinical demographics, imatinib treatment information, and contrast-
enhanced CT (baseline, two months and four months post imatinib initiation) were 
available.  From the mutational dataset, patients were excluded for the following 
reasons: a) patient received mutation testing at our institution, but clinical treatment 
at an outside center, b) GIST patient did not receive imatinib, c) patient was missing 
baseline, two-month, or four-month follow-up CT imaging, d) only non-contrast CT 
or very poor quality OSF CT was available for the patient, e) the patient underwent 
resection and there was no evidence of disease, f) the tumor contained air-
fluid/barium and was difficult to measure density and compare size, g) the existing 
lesions were too small (<2cm). Thus, we identified 95 patients for whom complete 
information was evaluable. 
 Characteristics of the patients evaluated in this study are presented in Table 
8 (n=95).  Males were slightly more frequent (52 men (55%) and 43 women (45%)) 
and the average age at treatment initiation was approximately 59 years old. 
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Figure 14. Unique KIT exon 9 mutations identified 
(A) Sequencing trace output is shown from KIT exon 9.  Most KIT exon 9 mutations 
reported to date in GIST are a single A502_Y503 duplication/insertion, shown on 
the right; (B) Two GIST patients exhibited the same S467I point mutation; (C) one 
GIST patient experienced a unique, previously-unreported six base-pair in-frame 
insertion that resulted in a A507_F508 duplication. 
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Table 8. Study Characteristics  
Characteristics of patients used for CT response assessment. As previously 
reported, KIT genotype was statistically associated with different primary tumor 
locations (p=0.042 by Fisher’s exact). 
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The majority of patients (n=76) were Caucasian (80%), with 11, 5, and 3 African 
American, Hispanic, and Asian patients included, respectively. Tumors occurred 
most frequently in gastric and small bowel tissues (41.1% and 44.2% of cases), 
while there were 12 tumors of the colorectum (12.6%), and 2 esophageal tumors 
(2.1%) identified.   
In total, 264 lesions from 95 patients were evaluated by CT.  Size (in 
centimeters) and density (in Hounsfield Units (HU)) measured at initiation of imatinib 
treatment were compared to two- and four-month follow-up CT scans.  All available 
lesions that were disease-characteristic, both primary and metastatic, were 
examined and measured per patient.  The most frequent site of metastasis was the 
liver (n=37 patients, 40%), followed by the peritoneum in 28 patients (30%). 15 
(16%) patients had metastasis at both these sites.  Another 15 (16%) patients were 
found to have disease elsewhere, including in lung, bone, lymph node and recurrent 
primary lesions. 
There were 70 patients whose tumor had KIT exon 11 mutation, 8 patients 
with KIT exon 9 mutation and 17 with wild-type KIT (74%, 8%, and 18% of patients, 
respectively).  Overall, 84 (88%) patients were considered responsive to imatinib 
treatment, as evaluated by either density or size alterations that met the Choi 
criteria for response (please refer to Table 6 for criteria summary), whereas 11 
patients did not respond and were classified as either SD or PD.  Subgroup 
analyses were then carried out to further stratify the data.  
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 The change in tumor size for each patient from baseline at imatinib treatment 
initiation to the four-month follow-up is presented in Figure 15 (A).  69 patients 
(73%) achieved a Choi PR by size change alone.  Less than 10% decrease, no 
change, or an increase in tumor size was observed in 26 patients (27%).  The 
change in tumor density over the same period is shown in Figure 15 (B), where 
density decreases qualified 73 patients as Choi PR (77%) and 22 patients (23%) 
experienced less than 15% decrease or an increase in tumor density.  
 In order to better understand the interactions between tumor size and density 
of GIST patients treated with imatinib, a graded combination measure of response 
was evaluated.  Patients’ combined percentage density and size changes were 
plotted together and scored according to the combined change of the tumor, 
presented in Figure 16.  Combined response Grade 1 was assigned to Choi 
responders with decreases ≤15%, Grade 2 corresponded to decreases 16-20%, 
Grade 3 decrease was 21-30%, Grade 4 was 31-40%, Grade 5 was 41-50% and so 
forth with each grade spanning 10 percentage points up to Grade 8. No penalty was 
assigned for increases in size or density, since decreases in tumor size can 
associate with increased tumor density in GIST and vice versa.  Natural breakpoints 
emerged which grouped Grade 1-4 (n=25), Grade 5-7 (n=32) and Grade 8 + (n=27).  
While exceptions were noted, the Grade 1-4 group included patients whose tumors 
moderately responded to imatinib, as well as a majority of responders whose tumor 
size/density responded in opposite fashion.  The Grade 5-7 group included patients 
most of whom had a response to imatinib, whereas the Grade 8+ group patients all 
experienced a robust response in both size and density decreases.  
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Figure 15. CT response changes in size and density 
(A) A waterfall plot of mean tumor size change (%) from baseline. The dashed line 
indicates ≥10% size decrease. Size decreases in 69 patients (73%) qualified as PR 
by Choi, compared to minimal size changes in 15 patients and size increases in 11 
patients; (B) A waterfall plot of mean tumor density change (%) from baseline.  The 
dashed line indicates ≥15% decrease, observed in 73 patients (77%). 
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Figure 16. Cumulative response comparison 
Percent change in density and size of GIST tumors are compared.  A cumulative 
grade was assigned to Choi responders based on decreases in size and density.  
Group 1-4 (n=25) had the most patients with mixed response, Grade 5-7 (n=32) 
experienced response, and Grade 8+ (n=27) patients were all combined responders 
and displayed the greatest decreases in size but also were found to have decreases 
in density.  
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 To examine whether KIT mutation influences the type of response in these 
GIST patients, as measured by CT, mutation characteristics such as location of 
individual mutations, specific codon altered, and type of alteration (missense, 
duplication, deletion) were each examined using the Choi response subgroups.  
First, patients with KIT exon 11 mutation (of any type, n=60) were compared to 
those expressing KIT exon 9 mutation (n=8) or wild-type KIT (n=17).  As 
summarized in Table 9, KIT genotype was significantly associated with type of 
response measured by CT (p=0.001 by Fisher’s exact test for Choi responder sub-
groups vs. non-responders).  While wild-type patients, whose tumors primarily 
responded with density changes, were fairly equally distributed between response 
groups, a majority of KIT exon 9 patients responded in the lowest response class 
(62.5% Response Grade1-4).  On the other hand, patients with KIT exon 11 mutant 
GIST responded with the largest size and density decreases, and 81.7% attained a 
response Grade 5 or higher (Figure 17).  
Next, subgroup analysis stratified KIT exon 11 patients into regions of focus 
of their mutation within KIT exon 11: N-terminus included all mutations affecting 
K550 to V560 (n=57), “M/C” included mutations altering the mid-region or C-
terminus of KIT exclusively, from E561 to V569 for mid-region, and Y570 to F591 for 
C-terminal region (n=10 for mutations residing in both regions).  These regions were 
distinguished by the natural pattern of mutation that was observed in the larger 
mutation group (see Figure 13).  Finally, a small group (n=3) of mutations that 
disrupted the entire length of KIT exon 11 were included for analysis (“pan”).  These 
pan-exon mutations deleted portions of all three regions of KIT exon 11 and patients  
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Table 9. Factors evaluated for radiographic response correlation 
For each comparison A-D, Choi response group versus non-responders were 
compared (a), then sub-groups of Choi responders were statistically considered 
against non-responders and each other (b). 
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Figure 17. Genotype is associated with grade of radiographic response 
KIT genotype was significantly associated with type of response measured by CT  
(p=0.001 by Fisher’s exact test for Choi responder sub-groups vs. non-responders). 
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with this mutation responded exclusively by size.  This comparison was not 
statistically significant  (p=0.109 by Fisher’s exact test for Choi responder sub-
groups vs. non-responders).  This may indicate that location of the mutation within 
KIT exon 11 may not be a predictive marker of imatinib response. 
Next, mutations that altered particular codons within KIT exon 11 were 
compared as to their relationship types of radiographic response to imatinib.  
Codons of interest were W557, V559/V560 (considered together), and L576 since 
these are the most common distinct mutations in KIT exon 11 of GIST.  Both W557 
and V559/V560 reside in the N-terminal region of KIT and are frequent points of 
alteration in GISTs, together representing 74% of KIT exon 11 mutations in our 
analysis.  W557_K558 is one of the most frequent alterations overall, and more 
mutations affect this codon through larger deletion in the region or missense 
mutation of W557.  Any change to W557 in this case, deletion or missense mutation 
was included (n=36, 51% of all KIT exon 11 mutations in this study).  Likewise, 
missense mutations affecting V559 or V560, and deletions affecting one or both 
valines were grouped together (n=16, 23%).  Finally, seven patients with alterations 
affecting L576 in the C-terminus were included.  Often a missense mutation, one 
duplication that affected L576 and one deletion were included (10% of our KIT exon 
11 group).  Radiographic response, when examined by response grade group 
versus non-responders, was significantly influenced by the type of codon changes 
examined (p=0.013 by Fisher’s exact test).  Over 80% of W557-altered tumors 
responded with a Grade 5 or higher, whereas nearly half of L576-mutated tumors 
fell in Grade 1-4, as shown in Figure 18.  V559/V560-mutations were split evenly 
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Figure 18. Specific codon alterations of KIT exon 11 correlate with response 
Over 80% of W557-altered tumors responded with a Grade 5 or higher, whereas 
nearly half of L576-mutated tumors fell in Grade 1-4 (p=0.013 by Fisher’s exact 
test).   
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between the lowest and highest response categories, which may indicate that an 
alteration to V559 does not affect V560 similarly, or again, specific types of 
alterations may discern the difference.  
In a fourth question, the type of mutational alteration in KIT exon 11, 
missense mutation, versus any deletion, versus duplication/insertions was 
examined.  As previously discussed, the frequency of these mutational changes 
does seem to correlate with region of KIT exon 11. Only 1 of 23 point mutations, 3 
of 40 deletions, and none of the four duplications were non-responders by Choi, and 
the comparison to radiographic response sub-groups was non-significant (p=0.504). 
Focus on specific density and size changes in patients’ metastases led to an 
inquiry about type of response in different metastatic sites.  Comparing patients who 
had both liver and peritoneal implants, it was noted that both metastatic sites 
maintained the same type of response within a given patient.  That is to say that 
both liver and peritoneal implants responded similarly in their size and density 
changes, in both responders and non-responders.   
Statistical comparison of all size changes showed no significant difference in 
size of liver implants as a group (-16.2±29.6% mean change) versus peritoneal 
implants (-25.8±25.3% mean change; p=1.0).  Likewise, density was not statistically 
significant between the two metastatic locations: liver -28.5±24.7% mean change 
versus peritoneal -34.5±27.5% mean change, p=0.27.   
Primary mutation was then used to stratify radiographic response by 
metastatic location.  KIT exon 11 mutant GIST responded, as before, with 
decreases in size and density in both metastasis sites of 20-30%. Comparing the 
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change in KIT exon 9 and wild-type revealed that density was not a significant 
factor, yet size changes were distinctly different. KIT exon 9 size decreased less 
than 5% in liver and increased 2.5% in peritoneal while WT conversely increased in 
liver (mean 12.4%) and deceased in peritoneal tissues (-8.3%).  ANOVA statistic 
showed both size alterations significant at p<0.01 for liver changes and p=0.01 for 
peritoneum.  The summary of these analyses is presented in Table 10. 
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Table 10. Characteristics that influence response  
Liver and peritoneal metastases did not experience distinct size or density changes 
when compares by location.  Stratified by KIT genotype, size changes were 
statistically different, where KIT wild-type tumors increased in liver and decreased in 
peritoneum and KIT exon 9 had conversely decreased size in liver compared to a 
slight mean increase in peritoneum. 
 75 
Chapter 4. Relationship of Imatinib Plasma Level to Outcome 
4.1  Introduction 
In patients with GIST, radiographic responses and PFS are correlated with 
imatinib trough level exposure. However, limited data are available regarding 
steady-state, adjusted imatinib levels (Adj-Cmin) in patients with gastrectomy, 
patients undergoing dose escalation, by patient dose level, and by subtype of KIT 
mutation (eg KIT exon 9), and GIST patients receiving concomitant medications.  
Therefore, we examined Adj-Cmin in 197 GIST patients to determine distribution in 
our patient population by dose level, after dose escalation, over time, and by 
modified response criteria (Choi Criteria). We hypothesize that standard dosing of 
imatinib in GIST patients results in sub-therapeutic treatment levels for some 
patients.  Higher imatinib plasma levels correlate with better clinical response. If the 
hypothesis is true, then clinical response, as assessed by CT (Choi Criteria), will be 
associated with higher imatinib plasma levels, irrespective of imatinib dose.  If the 
hypothesis is not true, then this may indicate resistance to the drug in some patients 
(ie secondary mutation present), which could be screened.  
4.2  Results 
 From May 2008 to September 2010, information was collected from 197 
GIST patients who underwent imatinib TDM at UTMDACC.  The baseline patient 
characteristics, characteristics of these patients’ disease and treatment 
characteristics are provided in Table 11. There was a slight male predominance in  
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Table 11. TDM patient, disease, and treatment characteristics  
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the group (108 M/89 F), patients were primarily Caucasian (83.2%) with median age 
at diagnosis of 55 and mean BSA of 2.0m2.  Mean BSA for men was 2.1m2, 
whereas mean BSA for women was 1.9m2 in this group.  Most patients experienced 
a gastric or small bowel primary tumor (40.6% and 46.7%, respectively) with a small 
number located in the colorectum (11.7%).  Two patients had primary GIST of the 
esophageus (1.0%).  Patients with metastatic disease accounted for 55.3% of the 
group (109 patients).  More than half of patients exhibited a KIT exon 11 mutation 
(112 patients, 56.9%), and 15 patients were identified with KIT exon 9 mutation.  
Twenty-eight patients were considered KIT wild-type (KIT exon 9, 11, 13, and 17 
negative), whereas mutation information was unavailable in 42 patients (either no 
tissue available or incomplete KIT sequencing to date).  There were no PDGFRA 
mutations identified in this cohort.  Less than 30% of patients underwent 
gastrectomy, partial or complete, as shown in Table 11. Starting imatinib doses in 
the group varied from 100 mg daily up to 800 mg daily, with a majority of patients 
(142) receiving 400 mg daily.  Patients underwent TDM over time and 48 patients 
experienced dose escalation as clinically indicated.  Individual imatinib trough levels 
were used for correlative analyses whereas a mean trough imatinib level at identical 
dose was obtained for each patient used in outcome analyses. 
Trough imatinib levels (Adj-Cmin) were obtained at 245 different patient time 
points, as shown in Table 12.  Mean Adj-Cmin increased as dose increased in these 
patients, where patients receiving less than 400 mg imatinib daily corresponded to 
851 ng/mL mean Adj-Cmin (n=20; range 200-2073 ng/mL), 400 mg daily imatinib 
corresponded to mean Adj-Cmin of 1224 ng/mL (n=151; range 189-3476 ng/mL),  
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Table 12. Range of trough imatinib levels observed 
Trough imatinib levels were measured at 245 different doses.  Broad interpatient 
variability of Adj-Cmin was observed, but while ranges overlapped, Adj-Cmin 
increased as dose increased. *Patients at known subtherapeutic levels due to 
tolerance were excluded from efficacy analysis. 
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600 mg daily imatinib corresponded to mean Adj-Cmin of 1793 ng/mL (n=34; range 
320-4088 ng/mL), and 800 mg daily imatinib or greater corresponded to mean Adj-
Cmin of 2773 ng/mL (n=40; range 679-7088 ng/mL). (Note total doses equal to 245 
for the 197 patients due to clinically-indicated dose escalation in some patients).  
While ranges overlapped, imatinib dose escalation corresponded with incremental 
Adj-Cmin means, as expected (p < 0.0001, Table 12). 
Covariate analysis revealed factors that correlated with imatinib plasma level 
included age of the patient (p=0.0003), gender (p < 0.0001), and imatinib dose (p < 
0.0001), represented in Table 13.  Age of the patient was shown to be a significant 
covariate, where every 10-year increase in age correlated with approximately 129 
ng/mL increase in trough level for similar patients at the same imatinib dose.  
Gender was also indicated to be a significant influencing covariate, where women 
experienced an estimated 388.1 ng/mL higher trough imatinib level compared with 
male patients (p<0.0001).  Modeling estimated that increasing imatinib dose would 
increase imatinib plasma concentrations by an estimated 430 ng/mL per 100 
milligram imatinib (p<0.0001).  Reduced hepatic function examined through bilirubin 
(>1.2 mg/dL) and ALT (>56 IU/L) did not significantly influence Adj-Cmin, however 
AST (>48 IU/L), available in only a subset of cases, was significantly associated 
with higher Adj-Cmin and estimated to increase levels as much as 221.1 ng/mL 
(p=0.04).  Renal metabolism of imatinib accounts for <10%, so it was not included in 
the analysis but may affect covariates.  While mean BSA was significantly different 
between women and men (p<0.0001), marginal effects modeling did not show BSA  
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Table 13. Covariates of trough imatinib level 
Covariates of trough imatinib level are summarized. The estimated change in trough 
imatinib level (estimated Adj-Cmin change in ng/mL) for a unit change in the 
covariate is shown. 
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to significantly correlate with trough imatinib level, so gender is significant 
independent of BSA but could be affected by other unknown covariates. 
   Since GIST patients frequently are co-administered drugs that are either 
CYP450 inhibitors or CYP450 inducers, which may inhibit or induce function of 
particular CYP450 isoenzymes, we examined the effect of CYP450 inhibitor, 
inducer, substrate drugs upon imatinib Adj-Cmin. The metabolism of many 
medications, including imatinib, is dependant upon the CYP450 enzymes found in 
the liver, as well as in the gastrointestinal tract.  Clinically significant drug 
interactions are largely a result of altered CYP450 metabolism and close monitoring 
is required when patients are given one or more drugs influenced by CYP450 
metabolism to avoid interaction and/or therapeutic failure.  Over half of patients 
were taking one or more CYP450 inhibitor (54.31%) or CYP450 substrate (61.93%) 
concomitant medications together with imatinib (Table 14). While 40 percent of 
patients took one or more CYP450 inducers, only 9.14 percent of these patients 
took CYP450 inducers known to be relevant to imatinib metabolism.  Marginal 
effects modeling showed that CYP450 inhibitors in this group did not statistically 
influence Adj-Cmin (p=0.2).  The presence of one or more CYP450 inducers or 
substrates did, however, influence Adj-Cmin significantly (p=0.01 and p=0.0002 for 
inducers and substrate comedications, respectively).  The presence of a CYP450 
inducer drug in addition to imatinib was estimated to decrease Adj-Cmin by 320 
ng/mL.  The presence of a CYP450 substrate drug was estimated to increase Adj-
Cmin by 267 ng/mL, which is of uncertain clinical relevance and may be due to 
competitive metabolism (Table 13). 
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Table 14. Concomitant medications 
Number of patients, percentage and type of coadministered CYP450 inhibitors, 
inducers, or substrates of are shown for each isozyme class. *Note: imatinib is itself 
an inhibitor of CYP2C9, CYP2D6, CYP3A4, and is processed by CYP3A4/3A5.  
Imatinib is excluded from these percentages, since all patients received imatinib.   
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Interestingly, factors that did not achieve statistical significance included BSA 
of the patient, duration of imatinib therapy, race, and gastrectomy, the latter of 
which could be due to the small patient sample. 
 Patients undergoing a planned dose escalation, for example following 
surgery, who were at a known less-than therapeutic dose at the time of TDM 
analysis were used for PK analysis exclusively and were excluded from any long-
term outcome analysis. 
 The distribution of Adj-Cmin in a subset of GIST patients with metastatic or 
unresectable disease (n=126), irrespective of dose, ranged from 272 ng/mL to 4582 
ng/mL with a mean of 1367 ng/mL (Figure 19).  The increasing distribution of Adj-
Cmin were then subdivided into quartiles for comparison (Q), where Q1 Adj-Cmin 
mean was 628 ng/mL (n=32; range 272-803 ng/mL), Q2 Adj-Cmin mean was 982 
ng/mL (n=31; range 803-1166 ng/mL), Q3 Adj-Cmin mean was 1449 ng/mL (n=32; 
range 1173-1758 ng/mL), and Q4 Adj-Cmin mean was 2429 ng/mL (n=31; range 
1772-4582 ng/mL). 
The trough imatinib level distribution in these patients with unresectable 
disease was examined by Choi response four months after initiation of imatinib 
therapy.  Response in GIST, assessed by Choi, is delineated by complete response 
(CR) or partial response (PR), whereas stable disease (SD) and progressive 
disease (PD) do not represent response, by definition (summarized previously in 
Table 6).  Two-thirds of patients experienced a PR (n=82 (65.1%)), whereas 21.4% 
exhibited SD (n=27 (21.4%)) and one patient was classified as PD (n=1 (0.8%)) at 
this time point.  Choi response was undeterminable in 16 patients (ND, 12.7%) who  
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Figure 19. Distribution of plasma levels in unresectable patients 
Distribution of trough imatinib levels in patients with metastatic of unresectable 
GIST (n=126). Quartile cutoffs and ranges are shown.  The median Adj-Cmin in this 
group (1170 ng/mL) is shown in blue.  The first-quartile cutoff (1100 ng/mL) 
suggested by Demetri et al(142) is represented in red for comparison. 
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underwent resection and were receiving adjuvant imatinib therapy and two patients 
who received a known sub-therapeutic imatinib dose due to toxicity were excluded 
from this evaluation.  Patients who experienced PR had a significantly higher Adj-
Cmin than those in the combined SD/PD group, where PR mean Adj-Cmin equaled 
1503.6 ng/mL compared to SD/PD mean Adj-Cmin of 1116.6 ng/mL (p=0.02).  While 
exceptions were noted, a majority of Choi non-responders clustered in the Q1 to 
mid-Q2 range (Figure 20). 
Overall in this group of patients, KIT exon 11 mutation was identified in 66 
patients, KIT exon 9 mutation in 10 patients, and 16 patients were considered KIT 
wild-type (no KIT exon 9, 11, 13, or 17 mutation was identified).  Of those, 78 
patients had CT response measured and the distribution of Adj-Cmin combined with 
response and mutation is shown in Figure 21.  SD/PD responders included 6 of 14 
KIT wild-type (42.8%), 2 of 8 exon 9 (25%) and 14 of 56 KIT exon 11 mutations 
(25%).  While a trend of more KIT wild-type was represented in this comparison, it 
was non-significant (p=0.393 by Fisher’s exact test). 
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Figure 20. Distribution of Adj-Cmin and Outcome 
Distribution of Adj-Cmin and Outcome: Response (Choi) is significantly associated 
with higher trough imatinib levels where PR versus SD/PD (mean Adj-Cmin 1503.6 
ng/mL versus 1116.6 ng/mL, p=0.02).  While exceptions were noted, a majority 
(75%) of SD/PD responders clustered in the lower two quartiles. Quartile cutoffs 
were established using the overall distribution of trough imatinib levels in 126 
patients with unresectable disease.  Patients inevaluable by CT (n=16) are 
excluded in this comparison.  The median Adj-Cmin of the overall distribution (1170 
ng/mL) is shown in blue.  The first-quartile cutoff (1100 ng/mL) suggested by 
Demetri et al(142) is represented in red for comparison. 
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Figure 21. Response distribution with KIT mutation 
KIT mutation was available in 92 patients included in efficacy analyses.  Where 
available, KIT mutation group (exon 11, exon 9 or wild-type) are represented 
graphically beneath each graph column, whereas the actual mutation identified is 
listed vertically on the left.  While a higher percentage of KIT wild-type patients were 
resented in the SD/PD response group, there was no statistical correlation. 
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Comparable to previous studies, patients with wild-type KIT progressed first 
and KIT exon 11 patients experienced a median PFS of 81 months (Figure 22).  
Interestingly, patients with KIT exon 9 mutation experienced a progression-free 
survival similar to that of KIT exon 11 mutation patients, likely due to the 800 mg 
imatinib baseline dose given this group upon identification of the mutation at 
UTMDACC (KIT exon 11 median PFS 81.2±10.7SEM, KIT exon 9 PFS 
55.2±15.0SEM).  As expected, KIT exon 9 patients experienced a higher imatinib 
Adj-Cmin, as summarized in the table below, showing that higher trough imatinib 
levels correlate with response in this mutation sub-group. 
Finally, OS and PFS for patients used in efficacy analysis, presented herein, 
are representative for GIST patients and indicate that our population is what one 
would expect clinically.  Analyses of overall and progression-free survival are 
provided in Figure 23.  The PFS of these patients sub-divided by quartile of the Adj-
Cmin distribution was evaluated, presented in Figure 24.  There was no significant 
difference in PFS of Q1-Q4, unlike similar studies, and this likely represents a 
selection bias in our population (190).  Having already observed that patients with 
PR have a significantly higher Adj-Cmin than those with SD/PD response, and that 
patients with KIT exon 9 mutation experienced higher PFS with higher doses of 
imatinib, a prospective trial would best address the long-term potential benefits of 
increased plasma imatinib concentration on response. 
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Figure 22. Improved PFS with higher imatinib exposure 
Patients harboring KIT exon 9 mutations experienced a PFS not statistically distinct 
from KIT exon 11 mutation patients when treated at higher imatinib doses (KIT exon 
11 median PFS 81.2±10.7SEM, KIT exon 9 PFS 55.2±15.0SEM).  KIT exon 9 
mutation patients treated at higher doses experience increased trough imatinib 
levels compared to other groups.  ND: no mutation information. 
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Figure 23. OS and PFS of patients included in efficacy analyses 
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Figure 24. PFS of patients by Adj-Cmin quartile 
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Chapter 5. Discussion and Conclusions 
These investigations have indicated that KIT genotype is significantly 
associated with the type of response determined by clinical evaluation, in this case 
CT.  Moreover, this observation was found to be independent of imatinib dose.  
Patients with KIT exon 11 mutations exhibited the most robust response, with 
decreases in both size and density (81.7% attained response grade 5 or higher), 
whereas patients harboring KIT exon 9 mutations responded more subtly, with over 
half in the lowest response group (62.5%).  Interestingly patients with no identified 
KIT mutation appeared to stratify into two distinct groups by CT response (p=0.001), 
an observation that has not yet been reported.  The presence of a group of patients 
with WT KIT that appeared to benefit from therapy with imatinib may indicate the 
presence of a mutation in an alternate exon of KIT that was not tested or mutation in 
another kinase susceptible to the inhibitor imatinib. 
Comparison of KIT exon 11 mutations in GIST patients reviewed at 
UTMDACC revealed that mutations clustered within regions across the exon where 
missense mutations and deletions were more frequent in the N-terminal region, 
insertion/duplications were commonly in the mid- to C-terminal region, and a few 
large deletions spanned across all three domains (“pan” group).  Analysis of 
radiographic response stratified by any mutation identified in one of these three 
regions was conducted, followed by response stratified by what type of change 
occurred (deletion versus missense mutation or insertion/duplication).  Both of these 
analyses were not statistically associated with radiographic response, so codons 
most frequently affected by mutation were examined (KIT exon 11 codons W557, 
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V559/V560, and L576).  Within KIT exon 11, mutations altering specific codons 
were significantly associated with radiographic response when examined using the 
graded response criteria. Over 80% of W557-altered tumors responded with a 
Grade 5 or higher, whereas nearly half of L576-mutated tumors fell in Grade 1-4  
(p=0.013).  This may indicate that the specific codon change is a superior predictor 
of imatinib response than where on KIT exon 11 the mutation occurs or whether the 
mutation is a deletion, insertion, or point mutation, further bolstered by the fact that 
regional comparison (n-terminal KIT exon 11 mutations versus mid/C-terminal) and 
mutations grouped by type (deletion or missense mutation versus insertion) was not 
statistically associated with clinical response.  Mutations in KIT induce 
conformational changes which not only activate the tyrosine kinase, but may also 
affect the interaction between imatinib and its binding sites on KIT (129).  In silico 
experiments with L576P have shown that this mutation renders a protein that 
harbors an imatinib binding affinity that is two times less than wild-type KIT (135).  It 
is conceivable that L576P alterations may require higher imatinib concentrations, or 
even alternate TKIs to achieve the same efficacy as imatinib against mutations at 
W557, although further research is necessary.  
Radiographic response in metastases varied based on location and KIT 
genotype.  Wild-type KIT metastases increased in size in liver, on average, while 
decreasing in the peritoneum (mean size change 12.4% versus -8.3%, 
respectively).  In the context of KIT exon 9 mutation, size decreased only 
moderately in liver but increased in the peritoneum (mean size change -4.8% 
versus 2.5%, respectively).  These changes were significant (p ≤ 0.01 for both liver 
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and peritoneum) compared to KIT exon 11 mutant GIST, which responded with 
decreases in size and density in both hepatic and peritoneal sites of 20 to 30%.  
The rationale as to why differential responses would be observed is not known.  
This may be due to the biology of the tumor cells that preferentially metastasize to 
the liver or peritoneum.  Alternatively, it may be due to the tissue environment that 
determines the changes in tumor size and density after imatinib therapy.  This is 
critical in the assessment of response rates that may be different between organs.  
Perhaps response criteria should be different for liver as compared to peritoneal 
metastases.  This is an area in need of further multidisciplinary investigation. 
Recently, there has been significant interest in establishing whether 
exposure of patients to imatinib, as measured by imatinib trough level (Adj-Cmin) 
may correlate with outcome. Since KIT genotype influences the binding of imatinib 
(129), the optimal plasma trough concentration of imatinib is likely to vary based on 
the KIT genotype of the individual patient.  In a group of metastatic or unresectable 
GIST patients presented herein, trough imatinib levels ranged from 256 – 4582 
ng/mL with a first quartile cutoff of 803 ng/mL, much lower than the published 
literature (142).  Examining response in this group, as measured by Choi, revealed 
that nearly 75% of non-responders (SD/PD) clustered in the lower two quartiles 
(<1166 ng/mL) and that patients who achieved a Choi response at four months 
experienced a significantly higher trough imatinib level (PR versus SD/PD mean 
Adj-Cmin 1503.6ng/mL vs. 1116.6ng/mL, p=0.02) irrespective of underlying 
genotype.  In chronic myelogenous leukemia where imatinib therapy is a standard 
of care for its inhibition of BCR-ABL, two studies have associated higher trough 
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imatinib levels with better cytogenetic and molecular responses, and improved 
event-free survival (139, 140).  This association was independent of imatinib dose, 
as highly variable plasma levels were observed at both 400 mg and 600 mg doses 
(139).  CML patients who achieved a complete cytogenetic response (CCyR) 
experienced significantly higher imatinib trough levels (mean 1009 ± 554 ng/mL) 
than those who did not achieve a CCyR (mean 812 ± 409 ng/mL) (140). Both 
studies suggested a therapeutic minimum threshold above 1000 ng/mL for trough 
imatinib level (139, 140).  Recently, in a study of 73 patients with advanced GIST 
who had been randomized to either imatinib 400 mg or imatinib 600 mg per day, 
Demetri and colleagues identified that patients in the lowest trough imatinib quartile 
(<1100 ng/mL) had a significantly shorter median time to progression (11.3 months) 
when compared to patients in the other three quartiles (30.6 months, p=0.0029) 
(142). 
  Mutation of KIT serves as an important predictive factor for clinical outcome. 
Previous studies have established rationale for initiating high-dose imatinib 
treatment in patients harboring KIT exon 9 mutations. Therefore, KIT mutation 
testing is determined clinically at many centers (53, 123, 133). Patients with KIT 
exon 9 mutation in our cohort received a median dose of 800 mg, experienced 
higher trough imatinib levels, and experienced a PFS that was not statistically 
different from that of patients whose tumors had a mutation in exon 11 of the KIT 
gene.  The previous GIST study identified that patients with KIT exon 11 mutations 
in the upper three quartiles (trough imatinib >1100 ng/mL), had a significantly higher 
clinical benefit rate than patients with KIT exon 11 mutations in the lowest quartile 
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(142). This was not observed in our study, but this may be due to differences in the 
treatment groups, survival bias, and patient selection.  
 Analyses were performed and identified a number of novel factors that 
correlate with trough imatinib levels.  For instance, older patients had higher trough 
imatinib levels than that of younger patients.  Moreover, female gender was 
associated with higher trough imatinib levels, which may explain a somewhat better 
clinical response in women as reported by others (123).  However, this observation 
may be a result of other covariates, such as renal function, body mass index, or 
other pharmacokinetic variables and should be studied in prospective trials.  High 
interpatient variability of trough imatinib levels independent of dose was observed, 
concordant with a smaller study in GIST (142).  AST (>48 IU/L) was shown to be 
associated with higher trough imatinib levels, which may be due to tissue or cellular 
damage in some patients.  Finally, imatinib trough levels were lower when co-
administered with CYP450 inducer drugs, whereas CYP450 substrates were 
associated with higher imatinib trough levels.  Taken together, these data suggest 
should be studied prospectively to determine clinical utility. 
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